Cancer nanomedicine: a review of nano-therapeutics and challenges ahead
M. Joyce Nirmala, Uma Kizhuveetil, Athira Johnson, G Balaji, R. Nagarajan, Vignesh Muthuvijayan
Abstract
active and passive mechanisms. Since FDA approval for Doxil®, several nano-therapeutics have been developed, and a few have received approval for use in cancer treatment. Along with liposomes, solid lipid nanoparticles, polymeric nanoparticles, and nanoemulsions, even newer techniques involving extracellular vesicles (EVs) and thermal nanomaterials are now being researched and implemented in practice. This review highlights the evolution and current status of cancer therapy, with a focus on clinical/pre-clinical nanomedicine cancer studies. Insight is also provided into the prospects in this regard.
Topics & Concepts
NanomedicineCancerMedicineCancer therapyNanotechnologySolid lipid nanoparticleNanocarriersCancer treatmentLiposomePharmacologyNanoparticleDrugMaterials scienceInternal medicineNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsExtracellular vesicles in disease